Gilead Sciences challenges compulsory licensing of its anti-COVID-19 drug in Russia

27 April 2021
gilead-big

US biotech Gilead Sciences (Nasdaq: GILD) has filed a lawsuit with the Russian Supreme Court challenging the decision of the Russian government to issue a license to the domestic drugmaker Pharmsynthez for the manufacture of its original anti-COVID-19 drug remdesivir without its consent, reports The Pharma Letter’s local correspondent.

On December, 31, 2020, Russian Prime Minister Mikhail Mishustin signed a decree giving the right to Pharmsynthez to produce an analogue of Gilead’s Veklury (remdesivir) under the Remdeform brand without permission from Gilead within a one-year period. The Russian firm began producing its generic in February this year.

In the decree, Mr Mishustin refers to the Russian Civil Code, which allows the use of such a mechanism in the interests of national security, while the patent holder will be provided with monetary compensation. The amount of compensation was not disclosed. This was the first time a compulsory license for the production of a drug was issued in Russia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical